Taysha Gene Therapies, Inc. SEC filings TSHA
Taysha Gene Therapies, Inc. has 401 filings in SEC EDGAR's recent list, going back to May 4, 2020. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFR14A | Filing | May 9, 2025 | — |
| EFFECT | Filing | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 20, 2024 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2024 | — |
| EFFECT | Filing | Sep 8, 2023 | — |
| CORRESP | Letter to the SEC | Sep 7, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2023 | — |
| D | Filing | Aug 25, 2023 | — |
| EFFECT | Filing | May 1, 2023 | — |
| CORRESP | Letter to the SEC | Apr 27, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 7, 2023 | — |
| D | Filing | Nov 7, 2022 | — |
| EFFECT | Filing | Oct 14, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 23, 2020 | — |
| EFFECT | Filing | Sep 23, 2020 | — |
| CERT | Filing | Sep 23, 2020 | — |
| CORRESP | Letter to the SEC | Sep 21, 2020 | — |
| CORRESP | Letter to the SEC | Sep 21, 2020 | — |
| 8-A12B | Filing | Sep 18, 2020 | — |
| CORRESP | Letter to the SEC | Sep 17, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2020 | — |
| SEC STAFF LETTER | Filing | Sep 11, 2020 | — |
| CORRESP | Letter to the SEC | Sep 8, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2020 | — |
| D | Filing | Aug 18, 2020 | — |
| DRS | Filing | Aug 3, 2020 | — |
| D | Filing | May 4, 2020 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TSHA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806310
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.